Dyspareunia: Causes, Diagnosis, and Evidence-Based Treatment for Painful Sex in Women

What Is Dyspareunia and How Common Is It?

Dyspareunia is defined as persistent or recurrent pain associated with sexual intercourse that causes personal distress. Estimates from population studies place lifetime prevalence between 10% and 28% in women of reproductive age, rising sharply after menopause. A 2017 analysis in the Journal of Sexual Medicine found that 45% of postmenopausal women reported pain or discomfort with vaginal intercourse. [1]

Pain may be superficial (at the vaginal opening or vulva), deep (in the pelvis or lower abdomen), or both. Superficial dyspareunia most often reflects vulvovaginal atrophy, vulvodynia, or vaginismus. Deep dyspareunia points toward endometriosis, pelvic inflammatory disease, uterine fibroids, or ovarian cysts. Classifying pain location at the first visit directs the diagnostic workup and shortens the time to effective treatment.

The DSM-5 merged dyspareunia and vaginismus into a single category called genito-pelvic pain/penetration disorder (GPPPD), though most clinical guidelines still use the individual labels for treatment planning. The American College of Obstetricians and Gynecologists (ACOG) Practice Bulletin 119 states that "dyspareunia is one of the most underreported and undertreated conditions in women's sexual health." [2] Under-reporting reflects stigma, provider discomfort, and incorrect assumptions that pain with intercourse is normal.

Genitourinary Syndrome of Menopause: The Leading Cause

GSM accounts for the majority of dyspareunia in peri- and postmenopausal women. The condition replaced the older term "vulvovaginal atrophy" because it better captures the full picture: dryness, burning, irritation, urinary urgency, and pain with penetration, all driven by declining estrogen.

Estrogen receptors are dense throughout the vulva, vagina, urethra, and bladder trigone. As circulating estradiol falls below roughly 50 pg/mL after menopause, vaginal epithelium thins from 30 or more cell layers to fewer than 10, surface glycogen drops, lactobacilli decline, and vaginal pH rises above 5. A landmark Menopause Society (formerly NAMS) position statement noted that without treatment, GSM does not resolve spontaneously and worsens over time. [3]

Low-dose vaginal estradiol is the guideline-recommended first-line agent. Options include:

• Vaginal estradiol tablet (Vagifem/Yuvafem): 10 mcg inserted nightly for 2 weeks, then twice weekly.
• Vaginal estradiol ring (Estring): releases 7.5 mcg/day; replaced every 90 days.
• Conjugated estrogen cream (Premarin vaginal): 0.5 g applied 2, 3 nights per week.
• DHEA (prasterone/Intrarosa): 6.5 mg vaginal insert nightly; FDA-approved 2016.

In the REJOICE trial (N=305), vaginal prasterone 6.5 mg reduced dyspareunia severity scores by 1.42 points versus 0.96 with placebo on a 0, 3 scale (P<0.001). [4] Systemic absorption of low-dose vaginal estradiol is minimal; measured serum estradiol typically remains within the postmenopausal range (<20 pg/mL), making it an option even in many women with a history of hormone-sensitive cancer, subject to oncologist guidance.

Ospemifene (Osphena) is an oral selective estrogen receptor modulator (SERM) dosed at 60 mg once daily with food. It acts as an estrogen agonist on vaginal tissue and as an antagonist in the breast. In the SMART-3 trial (N=652), ospemifene reduced the most bothersome symptom of dyspareunia by 35.8% compared with 21.5% for placebo at 12 weeks. [5] Ospemifene carries a black-box warning for endometrial effects in women with a uterus who also use systemic estrogen and for VTE risk, though absolute VTE incidence in trials was low.

Vaginismus and Pelvic Floor Dysfunction

Vaginismus is an involuntary contraction of the pelvic floor muscles around the vaginal introitus that makes penetration painful or impossible. It may be primary (lifelong, no prior painless penetration) or secondary (acquired after a period of normal function). Secondary vaginismus is frequently a sequela of untreated GSM, childbirth injury, or sexual trauma.

Diagnosis rests on clinical history plus a pelvic exam showing high-tone pelvic floor with tenderness on single-finger palpation. A cotton-swab test maps localized allodynia and differentiates vaginismus from vestibulodynia, which involves point tenderness restricted to the vestibule.

Pelvic floor physical therapy (PFPT) is the backbone of treatment. A trained pelvic floor physiotherapist uses manual myofascial release, internal soft-tissue mobilization, and a graduated dilator program (sizes 1 through 5 or 1 through 7, depending on the kit). A 2017 Cochrane systematic review concluded that PFPT produced clinically significant improvement in vaginismus symptoms across all included randomized trials, though reviewers noted small sample sizes. [6] Real-world completion rates in structured programs reach 80 to 90% for resolution of penetration pain when patients complete the full dilator progression over 8 to 16 weeks.

Adjunct options include:

• Topical lidocaine 2 to 4% gel applied 5 to 10 minutes before penetration to reduce reflex guarding.
• Botulinum toxin A injections to the levator ani (50, 100 units, typically repeated at 3-month intervals): reserved for refractory high-tone dysfunction; evidence is promising but trial sizes remain small.
• Cognitive behavioral therapy (CBT) and sex therapy to address catastrophizing, anticipatory anxiety, and relationship dynamics that perpetuate the pain-avoidance cycle.

Vulvodynia and Vestibulodynia

Vulvodynia means chronic vulvar pain lasting more than 3 months with no identifiable cause. Provoked vestibulodynia (PVD), the most common subtype, produces burning or stinging localized to the vestibule on touch or penetration. Prevalence estimates from population studies range from 7% to 16% of women. A 2014 study in the American Journal of Obstetrics and Gynecology (N=7,629) reported that 8.3% of women had experienced vulvodynia symptoms for more than 3 months. [7]

Pathophysiology involves peripheral sensitization of C-fiber nociceptors, often triggered by recurrent candidiasis, HPV exposure, or hormonal contraceptive use. Central sensitization can maintain pain long after the original trigger resolves.

Treatment is multimodal:

• PFPT as described above.
• Tricyclic antidepressants (amitriptyline 10 to 75 mg nightly) or duloxetine 30 to 60 mg daily for central sensitization.
• Topical gabapentin 2 to 6% compounded cream applied to the vestibule 3 times daily.
• Vestibulectomy (surgical excision of the vestibule) for refractory PVD: a meta-analysis in the Journal of Sexual Medicine (N=1,176 across 18 studies) reported 71% success rate, defined as painless intercourse at 6 to 12 months post-surgery. 8

Endometriosis and Deep Dyspareunia

Deep dyspareunia that worsens premenstrually or during menstruation raises strong suspicion for endometriosis, a condition affecting roughly 10% of reproductive-age women (approximately 190 million worldwide). According to a 2020 article in The Lancet, deep dyspareunia is present in 30 to 50% of women with surgically confirmed endometriosis. [9]

Diagnosis requires laparoscopy for definitive confirmation. Medical suppression with combined oral contraceptives (continuous cycling to suppress menses), progestins such as norethindrone acetate 5 mg daily, or GnRH agonists such as leuprolide 3.75 mg IM monthly (with add-back therapy) reduces dyspareunia by lowering ectopic implant activity. Sexual positioning changes (rear entry replaced by woman-on-top to control penetration depth) and pelvic support cushions can reduce mechanical pain in the interim.

Hypoactive Sexual Desire Disorder: When Low Desire Amplifies Pain

HSDD is classified separately from dyspareunia, but the two conditions frequently co-occur. A woman who anticipates pain will naturally reduce desire to avoid intercourse. Conversely, untreated HSDD produces low lubrication, raising friction and exacerbating GSM-related pain.

HSDD is defined as persistently low sexual desire causing personal distress, not better explained by a comorbid condition or medication. The HSDD Prevalence Study, published in Obstetrics and Gynecology (N=31,581), found HSDD in 8.9% of women aged 18, 44 to 12.3% aged 45, 64, and 7.4% aged 65 and older. [10]

Two FDA-approved pharmacologic options exist:

Flibanserin (Addyi), a non-hormonal serotonin 1A agonist and serotonin 2A antagonist, is approved for premenopausal women with HSDD. Dose: 100 mg orally at bedtime (bedtime administration reduces hypotension risk). In the pooled VIOLET and DAISY trials (N=1,378), flibanserin increased satisfying sexual events by 0.5 per month over placebo and decreased distress scores significantly at 24 weeks. [11] Alcohol must be avoided within 2 hours of the dose because of a serious hypotension/syncope interaction; prescribers must be certified under the REMS program.

Bremelanotide (Vyleesi), a melanocortin receptor agonist, is approved for premenopausal women as a 1.75 mg subcutaneous injection self-administered 45 minutes before anticipated sexual activity. It should not be used more than once in 24 hours. In the RECONNECT trials (N=1,227), bremelanotide increased desire scores by 0.3 on a 1.2-point scale versus 0.1 for placebo (P<0.001) and reduced distress. [12] Transient nausea occurs in about 40% of users; pre-treating with ondansetron 4 mg can help.

For postmenopausal women, off-label low-dose testosterone therapy (transdermal, 300 mcg/day gel or cream) has the strongest evidence base for HSDD, summarized in a 2019 Journal of Clinical Endocrinology and Metabolism consensus position paper that reviewed 36 randomized controlled trials. That consensus concluded testosterone was "the only pharmacological treatment with adequate trial evidence for HSDD in postmenopausal women." [13] No FDA-approved female testosterone product exists in the United States, so prescribing requires compounded formulations with careful serum monitoring to keep total testosterone below 80 ng/dL.

Female Orgasmic Disorder: Overlap and Distinction

Female orgasmic disorder (FOD) is defined as marked delay, infrequency, reduced intensity, or absence of orgasm during any sexual stimulation, causing distress. It co-exists with dyspareunia in roughly 35% of affected women. Pain during intercourse disrupts the arousal plateau necessary for orgasm, while FOD-related frustration can increase pelvic floor guarding and worsen pain.

A 2016 survey of 52,588 adults in the Archives of Sexual Behavior found that only 65% of heterosexual women reported usually or always orgasming during sexual encounters, compared with 95% of heterosexual men. [14] No FDA-approved pharmacotherapy exists specifically for FOD. Evidence-based interventions include directed masturbation therapy (an 8-session structured program), CBT targeting performance anxiety, and vibrator-assisted stimulation. When FOD is secondary to antidepressant use (most commonly SSRIs), dose reduction, switching to bupropion, or adding sildenafil 50 mg PRN (off-label) are the most studied strategies.

Diagnosing Dyspareunia: A Practical Clinical Approach

History-taking should cover pain onset, location (superficial vs. deep), quality (burning, stabbing, aching), timing relative to the cycle, and associated symptoms such as discharge, bleeding, or bladder symptoms. A structured sexual function questionnaire such as the Female Sexual Function Index (FSFI) captures six domains: desire, arousal, lubrication, orgasm, satisfaction, and pain. A total FSFI score below 26.55 identifies clinically significant sexual dysfunction.

The pelvic exam should be trauma-informed: explain each step in advance, use the smallest speculum appropriate, and allow the patient to direct pacing. Cotton-swab testing of the vestibule at clock positions (3, 6, 9, 12) differentiates localized vestibular hypersensitivity from diffuse vaginal atrophy. Single-finger palpation of the pelvic floor assesses tone and trigger points in levator ani, obturator internus, and the superficial perineal muscles.

Targeted investigations include vaginal pH (normal <4.5 premenopause; GSM typically pH 5, 7), vaginal cultures if discharge suggests bacterial vaginosis or candidiasis, and pelvic ultrasound if deep dyspareunia or pelvic mass is suspected. Serum FSH, estradiol, and total testosterone are useful baseline labs, particularly in perimenopause or when hormonal therapy is under consideration.

A stepwise triage framework used by the HealthRX clinical team categorizes dyspareunia into three tracks based on the exam:

• Track 1 (atrophic/GSM): Thin rugae, elevated pH, no tenderness on single-finger exam. Start vaginal estradiol or prasterone. Reassess at 8 weeks.
• Track 2 (pelvic floor/musculoskeletal): Normal vaginal mucosa, high-tone pelvic floor, positive cotton-swab test. Refer to PFPT within 2 weeks; add topical lidocaine for intercourse.
• Track 3 (structural/systemic): Deep pain, abnormal uterine contour, suspected endometriosis or fibroid. Pelvic ultrasound within 2 weeks; OB-GYN or REI referral.

These tracks are not mutually exclusive. GSM and pelvic floor hypertonia co-exist in a substantial proportion of perimenopausal women, and both tracks should be treated simultaneously when both are present.

Non-Pharmacologic and Behavioral Approaches

Vaginal moisturizers (polycarbophil-based, e.g., Replens) applied every 2 to 3 days reduce vaginal pH and improve epithelial hydration independently of hormones. A 2018 randomized trial in JAMA Internal Medicine (N=302) found vaginal moisturizer equivalent to vaginal estradiol for symptom improvement at 12 weeks in women with mild-to-moderate GSM, though estradiol produced greater objective tissue changes. 15

Personal lubricants reduce friction acutely but do not treat the underlying tissue. Silicone-based lubricants last longer than water-based formulations and are not absorbed. Avoid lubricants containing glycerin (raises osmolality, potentially disrupts epithelium) or benzocaine (contact allergy risk).

Mindfulness-based sex therapy (MBST) has been tested in three small RCTs for dyspareunia associated with provoked vestibulodynia. Women in the MBST arms reported greater reductions in pain catastrophizing and improved arousal compared with waitlist controls, though sample sizes were 50, 80 per study, limiting generalizability.

Regular sexual activity or vibrator use maintains vaginal blood flow and preserves epithelial thickness. Orgasm and arousal increase vaginal transudate production. For women without a partner or those whose partner is unable to engage, vibrator use 3, 4 times per week is clinically appropriate guidance.

Special Populations: Breast Cancer Survivors

Breast cancer survivors deserve a specific note because GSM prevalence in this group reaches 60 to 80% due to chemotherapy-induced ovarian failure, aromatase inhibitor use, or surgical menopause. Many oncologists restrict systemic and vaginal estrogen. The 2022 ACOG Committee Opinion on Vaginal Estrogen in Breast Cancer Survivors states that "for women with a history of estrogen-receptor-positive breast cancer, low-dose vaginal estrogen may be considered after shared decision-making with the oncology team when non-hormonal options have been inadequate." [16]

Non-hormonal first-line options for this population include:

• Vaginal prasterone (converts locally to androgens and estrogen at tissue level with minimal systemic absorption).
• Ospemifene: not recommended in women with estrogen-receptor-positive breast cancer per current labeling.
• Pelvic floor PT, vaginal moisturizer, and silicone lubricant as described above.
• Compounded vaginal testosterone 150 to 300 mcg/day: limited data but under investigation.

Monitoring, Follow-Up, and When to Escalate

Symptom reassessment at 8 to 12 weeks for pharmacologic treatment and 16 weeks for PFPT gives adequate time to judge response. Use FSFI pain subscale scores as a quantitative outcome. A pain subscale score improving from below 3.8 (dysfunction threshold) to above 5.0 represents a clinically meaningful response.

Escalate to subspecialty care (urogynecology, sexual medicine, pain management, or REI) when:

• Two sequential pharmacologic agents at adequate dose and duration have failed.
• Pelvic floor PT has been completed (minimum 8 sessions) without adequate response.
• Deep dyspareunia is worsening or accompanied by pelvic mass on imaging.
• Significant psychological comorbidities (PTSD, severe depression) require concurrent psychiatric management.

A DEXA scan to assess bone mineral density is appropriate for any woman who has been amenorrheic for more than 12 months and is not on hormone therapy, given the dual impact of estrogen deficiency on bone and vaginal tissue.

Baseline and annual serum total testosterone are warranted if testosterone therapy is started, targeting a level of 20 to 80 ng/dL (the upper limit of the normal female range). Polycythemia and acne are the most common adverse effects at supraphysiologic levels.